Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicaid Rx Spending Increases To $15.5 Bil. In 1998; 9.1% Of Total Costs

Executive Summary

Prescription drugs accounted for 9.1% of Medicaid spending in 1998, according to a study authored by the Health Care Financing Administration Health Statistics Group, published in the January issue of Health Affairs.

You may also be interested in...



PhRMA Moves To Head Off Clinton Assault; Considers Incremental Rx Benefit

The Pharmaceutical Research & Manufacturers of America is attempting to defuse some of the Clinton Administration's rhetoric on drug costs to the elderly ahead of the State of the Union address.

Medicaid rebates running at 20% in Michigan; Rx spending up 4% despite 7% drop in scripts.

MICHIGAN MEDICAID REBATES RUNNING AT 20% OF PHARMACEUTICAL EXPENDITURES through fiscal 1997, according to program figures released at the University of South Carolina public policy conference in Hilton Head, S.C. Michigan calculated that it received $72.8 mil. in rebates for FY 1997 out of total drug expenditures of $365.3 mil. The figure includes estimated payments during the fourth quarter. Medicaid agencies receive a minimum 15.1% rebate on pharmaceuticals, and are entitled to rebates matching the manufacturer's "best price."

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

IV001392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel